DrugCite
Search

LOCHOL

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Lochol Adverse Events Reported to the FDA Over Time

How are Lochol adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Lochol, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Lochol is flagged as the suspect drug causing the adverse event.

Most Common Lochol Adverse Events Reported to the FDA

What are the most common Lochol adverse events reported to the FDA?

Alanine Aminotransferase Increased
80 (3.32%)
Blood Creatine Phosphokinase Increa...
80 (3.32%)
Aspartate Aminotransferase Increase...
77 (3.19%)
Hepatic Function Abnormal
60 (2.49%)
Blood Lactate Dehydrogenase Increas...
54 (2.24%)
Malaise
48 (1.99%)
Blood Creatinine Increased
46 (1.91%)
Gamma-glutamyltransferase Increased
44 (1.82%)
Rhabdomyolysis
44 (1.82%)
Blood Alkaline Phosphatase Increase...
39 (1.62%)
Pyrexia
36 (1.49%)
Show More Show More
Liver Disorder
31 (1.29%)
Blood Urea Increased
24 (1%)
Dizziness
23 (.95%)
Blood Bilirubin Increased
19 (.79%)
Decreased Appetite
19 (.79%)
Chromaturia
18 (.75%)
Dyspnoea
18 (.75%)
Platelet Count Decreased
18 (.75%)
Gait Disturbance
17 (.71%)
Headache
17 (.71%)
Hypoaesthesia
17 (.71%)
White Blood Cell Count Decreased
17 (.71%)
Blood Pressure Increased
16 (.66%)
Abdominal Pain Upper
15 (.62%)
Haemoglobin Decreased
15 (.62%)
Hemiparesis
15 (.62%)
Interstitial Lung Disease
15 (.62%)
Renal Impairment
15 (.62%)
Fall
14 (.58%)
Myoglobin Blood Increased
14 (.58%)
Pancytopenia
14 (.58%)
Vomiting
14 (.58%)
Anorexia
13 (.54%)
Diarrhoea
13 (.54%)
Myalgia
13 (.54%)
Asthma
12 (.5%)
Blood Beta-d-glucan Increased
12 (.5%)
Cholelithiasis
12 (.5%)
Cough
12 (.5%)
Fatigue
12 (.5%)
Nausea
12 (.5%)
Thrombotic Stroke
12 (.5%)
Anaemia
11 (.46%)
Back Pain
11 (.46%)
Blood Pressure Decreased
11 (.46%)
Muscular Weakness
11 (.46%)
Myoglobin Urine Present
11 (.46%)
Nephrotic Syndrome
11 (.46%)
Thrombocytopenia
11 (.46%)
White Blood Cell Count Increased
11 (.46%)
Abdominal Pain
10 (.41%)
Blood Potassium Increased
10 (.41%)
Brain Stem Infarction
10 (.41%)
C-reactive Protein Increased
10 (.41%)
Cytomegalovirus Viraemia
10 (.41%)
Focal Segmental Glomerulosclerosis
10 (.41%)
Musculoskeletal Stiffness
10 (.41%)
Pneumocystis Jiroveci Pneumonia
10 (.41%)
Pneumonia
10 (.41%)
Tracheobronchitis
10 (.41%)
Asthenia
9 (.37%)
Autoimmune Hepatitis
9 (.37%)
Blood Glucose Increased
9 (.37%)
Condition Aggravated
9 (.37%)
Haemodialysis
9 (.37%)
Jaundice
9 (.37%)
Muscle Spasms
9 (.37%)
Palpitations
9 (.37%)
Quadriplegia
9 (.37%)
Septic Shock
9 (.37%)
Shock
9 (.37%)
Surgery
9 (.37%)
Blood Cholesterol Increased
8 (.33%)
Blood Creatine Phosphokinase Mb Inc...
8 (.33%)
Blood Immunoglobulin G Increased
8 (.33%)
Chest Pain
8 (.33%)
Creatinine Renal Clearance Decrease...
8 (.33%)
Eye Disorder
8 (.33%)
Eye Inflammation
8 (.33%)
Eye Pain
8 (.33%)
Oedema Peripheral
8 (.33%)
Protein Urine Present
8 (.33%)
Red Blood Cell Count Decreased
8 (.33%)
Renal Failure Acute
8 (.33%)
Uveitis
8 (.33%)
Vitreous Opacities
8 (.33%)
Antinuclear Antibody Positive
7 (.29%)
Chest X-ray Abnormal
7 (.29%)
Concomitant Disease Progression
7 (.29%)
Glucose Urine Present
7 (.29%)
Hypercholesterolaemia
7 (.29%)
Inflammation
7 (.29%)
Liver Function Test Abnormal
7 (.29%)
Pain In Extremity
7 (.29%)
Tumour Excision
7 (.29%)
Viith Nerve Paralysis
7 (.29%)
Vision Blurred
7 (.29%)
Visual Acuity Reduced
7 (.29%)
Bile Duct Stone
6 (.25%)
Blindness
6 (.25%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Lochol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lochol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Lochol

What are the most common Lochol adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Lochol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lochol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Lochol According to Those Reporting Adverse Events

Why are people taking Lochol, according to those reporting adverse events to the FDA?

Hypercholesterolaemia
258
Hyperlipidaemia
126
Dyslipidaemia
37
Lipids Abnormal
11
Angina Pectoris
5
Drug Use For Unknown Indication
4
Show More Show More
Hypertension
3
Product Used For Unknown Indication
3
Prophylaxis
3
Blood Cholesterol Increased
2
Cardiovascular Disorder
2
Transient Ischaemic Attack
2
Hepatic Function Abnormal
2
Atrial Fibrillation
2
Cardiac Valve Disease
2
Blood Cholesterol Decreased
1
Hepatitis C
1
Blood Cholesterol
1
Lacunar Infarction
1
Low Density Lipoprotein Increased
1
Blood Triglycerides Increased
1

Lochol Case Reports

What Lochol safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Lochol. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Lochol.